Treatment Action Campaign (TAC) chairperson Zackie Achmat and deputy chair Sipho Mthathi expressed the organization’€™s anger at the confusion sown by recent statements from the health minister and the Medicines Control Council.

‘€œWe did not want another controversy when we came here [to Bangkok] but that’€™s what’€™s happened,’€ said an angry Achmat. Earlier in the day he had appealed to conference delegates to support a ‘€œscience and human rights-based approach’€ to health policy and implementation in South Africa.

Achmat said the TAC was angry because prior to the AIDS conference there had been an agreement with provincial heads of health at MinMEC that potentially sensitive issues would be discussed in a reasonable way at the international conference and that the focus would be on scaling up South Africa’€™s comprehensive plan to care and treat for people living with HIV/AIDS.

‘€œWhat has happened was an undermining of that agreement and that is why we are so angry,’€ he said.

UN Special Envoy on HIV/AIDS Stephen Lewis said the world watched in ‘€œsome bewilderment’€ at the ‘€œconfusion, obfuscation, complication and controversy’€ that surrounded the latest episode on nevirapine and the health ministry.

He said it was a ‘€œdeep irony’€ that impoverished countries around South Africa that did not have the same capacity were doing their utmost to provide antiretroviral treatment to their citizens.

‘€œIt seems almost unbearable that those who survived the cancer of apartheid lived to die from a communicable disease,’€ said Lewis. It was a situation which ‘€œthe world begs you to resolve’€, he added.

Stung by criticism that TAC actions were unpatriotic and designed to embarrass the South African government on international platforms, Mthathi said the health minister’€™s actions and lack of determination to implement antiretroviral treatment were a cause of greater embarrassment.

Both MCC Registrar Precious Motsoso and Gauteng MEC for health Gwen Ramagopa addressed the meeting from the floor to assure South Africans that programmes to prevent the transmission of HIV from mother to child would be revised only in the best interests of South African mothers and children.

Motsoso   clarified that nevirapine would continue being used for antiretroviral therapy treatment but that it was not recommended as a single dose in mother to child HIV prevention. She said there was no intention to de-register the drug.